Recently, several studies have shown a relationship between high levels of adrenomedullin and severity of illness and mortality in hospitalised COVID-19 patients [23, 24], and adrecizumab has been tested as a treatment for severe COVID-19 ARDS in a small uncontrolled case series [25]. The gene discussed is ADM; the disease is COVID-19.